TERIPARATID Mepha sol inj 250 mcg/ml 2.4 ml

7680661020017 CH-66102 H05AA02 07.99.0.

Active substances:

TERIPARATID Mepha sol inj 250 mcg/ml 2.4 ml
TERIPARATID Mepha sol inj 250 mcg/ml 2.4 ml
TERIPARATID Mepha sol inj 250 mcg/ml 2.4 ml
1 / 3
google

Details

Product number
6610201
CPT
-
Packaging group
1
Unit
Injektor(en), vorgefüllt/Pen
Composition
teriparatidum 250 µg ut teriparatidi acetas, acidum aceticum glaciale, natrii acetas trihydricus, mannitolum, metacresolum, acidum hydrochloridum aut natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 0.09 mg.

Articles (1)

Teriparatid-Mepha, Injektionslösung im Fertigpen
Injektionslösung im Fertigpen
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
02/09/2026
Patient information leaflet
Français
02/09/2026
Patient information leaflet
Italien
02/09/2026
Professional SmPC
Allemand
29/08/2026
Professional SmPC
Français
29/08/2026
Professional SmPC
Italien
29/08/2026

Detailed composition

Substance Quantity Type Category
teriparatidum
250.0 UG Substance Wirkstoff (Principe actif)
teriparatidi acetas
- Substance WIZUS
acidum aceticum glaciale
- Substance HNIDK
natrii acetas trihydricus
- Substance HNIDK
mannitolum
- Substance HNIDK
metacresolum
- Substance Konservierungsstoff (Conservateur)
acidum hydrochloridum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
0.09 MG Substance HBESI

Reimbursement information

Public price
CHF 225.60
Specialties list
Yes
Generic
Yes

Reimbursement limitation

SL addition date: 01/07/2020

Authorization holder

Mepha Pharma AG

4051 Basel

Authorization information

Swissmedic authorization number
66102
Drug name
Teriparatid-Mepha, Injektionslösung im Fertigpen
Galenic form
INLFP
ATC Code
H05AA02
Authorization status
Z
Dispensation category
B
First authorization
17/11/2017
Authorization expiration date
31/12/9999
IT number
07.99.0.
Domain
Human medicine
Field of application
Postmenopausale Osteoporose bei Frauen; primäre und hypogonadale Osteoporose bei Männern. Glukokortikoid-induzierte Osteoporose bei Erwachsenen mit erhöhtem Frakturrisiko

Packaging details

Description (FR)
TERIPARATID Mepha sol inj 250 mcg/ml 2.4 ml
Description (DE)
TERIPARATID Mepha Inj Lös 250 mcg/ml 2.4 ml
Market launch
17/11/2017
Narcotic (BTM)
No

Original drug

Forsteo, solution injectable en stylo prérempli
CHF 305.75
View original
Buy us a coffee Explore the data